Cullinan Therapeutics
NASDAQ: CGEMIncorporated in Delaware · 4 known investors
Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers. Its focus areas include immune modulation approaches for conditions such as refractory lupus (SLE) and rheumatoid arthritis.
Investors · 4
Competitors · 2
by search overlapKite Pharma53 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
C4 Therapeutics41 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Companies competing with Cullinan Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Acquisitions · 1
Early investors' stakes continue via these dealsPDI Therapeutics
Developed a first-in-class monoclonal antibody for multiple cancers; acquired by Cullinan Therapeutics in 2022.
In the news
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Cullinan Therapeutics do?
- Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers. Its focus areas include immune modulation approaches for conditions such as refractory lupus (SLE) and rheumatoid arthritis.
- Who are Cullinan Therapeutics's investors?
- Cullinan Therapeutics's investors include Foresite Capital, Nextech Invest, Biotechnology Value Fund, OrbiMed.